araag2/HINT huggingface dataset:
Clinical trial NCT03349060 (phase 3, status: completed)
Conditions: dermatitis, atopic
ICD codes: L20.89, L20.9
Drugs: pf-04965842 100 mg, pf-04965842 200 mg, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  12 years of age or older with a minimum body weight of 40 kg

          -  Diagnosis of atopic dermatitis (AD) for at least 1 year and current status of moderate
             to severe disease (>= the following scores: BSA 10%, IGA 3, EASI 16, Pruritus NRS 4)

          -  Recent history of inadequate response or inability to tolerate topical AD treatments
             or require systemic treatments for AD control

        Exclusion Criteria:

          -  Unwilling to discontinue current AD medications prior to the study or require
             treatment with prohibited medications during the study

          -  Prior treatment with JAK inhibitors

          -  Other active nonAD inflammatory skin diseases or conditions affecting skin

          -  Medical history including thrombocytopenia, coagulopathy or platelet dysfunction, Q
             wave interval abnormalities, current or history of certain infections, cancer,
             lymphoproliferative disorders and other medical conditions at the discretion of the
             investigator

          -  Pregnant or breastfeeding women, or women of childbearing potential who are unwilling
             to use contraception
Clinical trial NCT03378635 (phase 3, status: completed)
Conditions: hypoglycemia, diabetes mellitus, type 1
ICD codes: E16.1, E16.2, P70.3, P70.4, E16.0, E10.641, E10.649, E10.65, E10.9, E10.21, E10.36, E10.41, E10.42, E10.44
Drugs: dasiglucagon, glucagen, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Female or male subjects with T1DM for at least 1 year, diagnostic criteria as defined
             by the American Diabetes Association

          -  Treated with insulin for T1DM for at least 1 year and with stable insulin treatment
             (defined as no more than a 10-unit daily variation in total daily insulin dose) 30
             days prior to screening

          -  Hemoglobin A1c <10%

        Exclusion Criteria:

          -  Previously treated with dasiglucagon (previously referred to as ZP4207)

          -  Known or suspected allergy to trial product(s) or related products

          -  Females who are pregnant according to a positive pregnancy test, are actively
             attempting to get pregnant, or are lactating.

          -  History of hypoglycemic events associated with seizures in the last year prior to
             screening

          -  History of severe hypoglycemia in the last month prior to screening

          -  Active malignancy within the last 5 years

          -  Current bleeding disorder, including anti-coagulant treatment

          -  Known presence or history of pheochromocytoma (i.e. adrenal gland tumor) or insulinoma
             (i.e. insulin secreting pancreas tumor)

          -  Use of a daily systemic beta-blocker drug, indomethacin, warfarin or anticholinergic
             drugs in the previous 28 days before Day 1 of this trial

          -  Clinically significant abnormal ECG at screening as judged by the investigator

          -  Donation of blood or plasma in the past month, or in excess of 500 mL within 12 weeks
             prior to screening

          -  Surgery or trauma with significant blood loss within the last 2 months prior to
             screening

          -  A positive result in the alcohol and/or urine drug screen at the screening visit.
             Significant history of alcoholism or drug abuse as judged by the investigator or
             consuming more than 24 g alcohol per day for men, or more than 12 g alcohol per day
             for women
Clinical trial NCT03399370 (phase 3, status: completed)
Conditions: ascvd, elevated cholesterol
ICD codes: E78.70, E78.79, K82.4
Drugs: inclisiran sodium, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          1. Male or female participants ≥18 years of age.

          2. History of ASCVD (coronary heart disease [CHD], cardiovascular disease [CVD], or
             peripheral arterial disease [PAD]).

          3. Serum LDL-C ≥1.8 millimole (mmol)/liter (L) (≥70 mg/dL).

          4. Fasting triglyceride <4.52 mmol/L (<400 mg/dL) at screening.

          5. Participants on statins should be receiving a maximally tolerated dose.

          6. Participants not receiving statins must have documented evidence of intolerance to all
             doses of at least 2 different statins.

          7. Subjects on lipid-lower therapies (such as a statin and/or ezetimibe) should be on a
             stable dose for ≥30 days before screening with no planned medication or dose change
             during study participation.

        Exclusion Criteria:

          1. New York Heart Association (NYHA) class IV heart failure.

          2. Uncontrolled cardiac arrhythmia

          3. Uncontrolled severe hypertension

          4. Active liver disease

          5. Females who are pregnant or nursing, or who are of childbearing potential and
             unwilling to use at least 2 methods of highly effective contraception (failure rate
             less than 1% per year) (for example, combined oral contraceptives, barrier methods,
             approved contraceptive implant, long-term injectable contraception, or intrauterine
             device) for the entire duration of the study. Exemptions from this criterion:

               1. Women >2 years postmenopausal (defined as 1 year or longer since last menstrual
                  period) and more than 55 years of age.

               2. Postmenopausal women (as defined above) and less than 55 years of age with a
                  negative pregnancy test within 24 hours of randomization.

               3. Women who are surgically sterilized at least 3 months prior to enrollment.

          6. Males who are unwilling to use an acceptable method of birth control during the entire
             study period (such as condom with spermicide).

          7. Treatment with other investigational products or devices within 30 days or 5
             half-lives of the screening visit, whichever is longer.

          8. Treatment (within 90 days of screening) with monoclonal antibodies directed towards
             PCSK9

        The above information is not intended to contain all considerations relevant to a
        participant's potential participation in a clinical trial.
Clinical trial NCT03399786 (phase 3, status: completed)
Conditions: homozygous familial hypercholesterolemia
ICD codes: E78.01, E78.00, Z83.42
Drugs: evinacumab, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Key Inclusion Criteria:

          1. Diagnosis of functional HoFH

          2. If undergoing LDL apheresis, must have initiated LDL apheresis at least 3 months prior
             to screening and must have been on a stable weekly or every other week schedule and/or
             stable settings for at least 8 weeks

          3. Willing to consistently maintain his/her usual low fat or heart-healthy diet for the
             duration of the study

        Key Exclusion Criteria:

          1. LDL-C level <70 mg/dL (1.81 mmol/L) at the screening visit

          2. Background medical Lipid Modifying Therapy (LMT) (if applicable) that has not been
             stable before the screening visit

          3. Lipid-apheresis schedule /apheresis settings (if applicable) that have not been stable
             for at least 8 weeks before the screening visit

          4. Use of nutraceuticals or over-the-counter therapies known to affect lipids, at a
             dose/amount that has not been stable for at least 4 weeks prior to the screening visit

          5. Presence of any clinically significant uncontrolled endocrine disease known to
             influence serum lipids or lipoproteins

          6. Newly diagnosed (within 3 months prior to randomization visit) diabetes mellitus or
             poorly controlled (HbA1c >9%) diabetes

          7. History of a MI, unstable angina leading to hospitalization, coronary artery bypass
             graft surgery, percutaneous coronary intervention, uncontrolled cardiac arrhythmia,
             carotid surgery or stenting, stroke, transient ischemic attack, valve replacement
             surgery, carotid revascularization, endovascular procedure or surgical intervention
             for peripheral vascular disease within 3 months prior to the screening visit

          8. Pregnant or breastfeeding women

          9. Sexually active women of child bearing potential (WOCBP), who are unwilling to
             practice a highly effective birth control method prior to the initial dose, during the
             study, and for 24 weeks after the last dose of study drug

         10. Men who are sexually active with women of child bearing potential (WOCBP) and are
             unwilling to consistently use condoms during the study drug treatment period and for
             24 weeks after the last dose of study drug regardless of vasectomy status

        Note: Other protocol defined inclusion/exclusion criteria may apply.
Clinical trial NCT03402204 (phase 3, status: completed)
Conditions: ischemic stroke
ICD codes: I25.5, H47.013, H93.013, G45.9, H47.011, H47.012, H47.019
Drugs: simvastatin 10 mg, simvastatin 40 mg
SMILES: [H][C@@](N)(CC1=CC=CC=C1)[C@]([H])(O)C(O)=N[C@@]([H])(CC(C)C)C(O)=O, [H][C@@](N)(CC1=CC=CC=C1)[C@]([H])(O)C(O)=N[C@@]([H])(CC(C)C)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patient with acute ischemic stroke has symptom onset less than 24 hours.

          -  Patient has 18 to 85 years old.

          -  Patient has been obtained describe the study and sign on informed consent.

        Exclusion Criteria:

          -  Patient has indication for simvastatin or ya-hom-navakote.

          -  Patient has pre-stroke mRS score more than 1.

          -  Patient was enrolled in other study within 30 days ago.

          -  Researchers consider that could be harmed by the participants or have certain
             conditions that could affect the participation in research, such as last stage of
             cancer.

          -  According to medical research suggests that patients unable to cooperate in research
             or inappropriate in joint research with other causes.

          -  Conscious level has >2 scores on question 2 of NIHSS.

          -  Platelet counts have less than 100,000 cells per cubic milliliter.

          -  Hematocrit has less than 0.25

          -  Blood sugar (BS) has less than 60 mg/dl or more than 200 ml/dl or between 200 and 300
             mg/dl and treated with diabetes drug until the BS levels have less than 200 mg/dl can
             include for the project before receive the researched drug.

          -  Patient with uncontrolled hypertension by measure systolic blood pressure (SBP) has
             more than 200 mmHg and/or diastolic blood pressure (DBP) has more than 110 mmHg before
             receive the researched drug or patient that receive aggressive treatment.

          -  Patient with others stroke or severe head injury within 6 weeks before enrolled to the
             project.

          -  Patient is received severe surgery within 14 days before enrolled to the project.

          -  Patient has seizure with acute ischemic stroke.

          -  Patient has acute myocardial infarction (AMI) or coronary heart disease (CHD) within 3
             weeks before enrolled to the project.

          -  Patient who receives lower-lipid level drug i.e. Ezetrol, Fenofibrate, Gemfibrosil,
             and Niacin or statin drugs i.e. Atorvastatin and Pitavastatin.

          -  Patient has increasing liver enzyme level or liver abnormal disease.
Clinical trial NCT03405935 (phase 3, status: completed)
Conditions: hiv-1 infection
ICD codes: B20, Z71.7, O98.72, Z21, O98.73, R75, Z11.4
Drugs: b/f/taf
SMILES: CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
Eligibility criteria:

        Key Inclusion Criteria:

          -  Currently receiving an antiretroviral regimen of E/C/F/TAF FDC (or emtricitabine
             [FTC]/TDF + 3rd agent if currently or previously participated in Study GS-US-292-1826
             [NCT02616783]) for ≥ 3 months

          -  Documented plasma HIV-1 ribonucleic acid (RNA) < 50 copies/mL during treatment with
             E/C/F/TAF (or FTC/TDF + 3rd agent if currently or previously participated in Study
             GS-US-292-1826 [NCT02616783]) for the last 2 visits preceding the screening visit (or
             undetectable HIV-1 RNA level according to the local assay being used if the limit of
             detection is ≥ 50 copies/mL)

          -  Adequate renal function, an estimated glomerular filtration rate (eGFR) ≥ 30 mL/min
             according to the Cockcroft-Gault formula for creatinine clearance

        Key Exclusion Criteria:

          -  An opportunistic illness indicative of stage 3 HIV diagnosed within the 30 days prior
             to screening

          -  Decompensated cirrhosis (eg, ascites, encephalopathy, or variceal bleeding)

          -  Current alcohol or substance use judged by the investigator to potentially interfere
             with participant study compliance

        Note: Other protocol defined Inclusion/ Exclusion criteria may apply.
Clinical trial NCT03409679 (phase 3, status: terminated)
Conditions: pneumonia
ICD codes: A01.03, A02.22, A54.84, B01.2, B06.81, B77.81, J12.0
Drugs: murepavadin, two anti-pseudomonal antibiotics
SMILES: CCS(=O)(=O)CCN1C(C)=NC=C1[N+]([O-])=O
Reason stopped: 
    safety data review
  
Eligibility criteria:

        Key Inclusion Criteria:

          -  Subject has received mechanical ventilation for at least 48h at the time of the
             randomisation

          -  Acute Physiology and Chronic Health Evaluation (APACHE) of 8 to 30, inclusive, within
             24h prior to randomization

          -  Presence of new or progressive infiltrate on chest X-ray

          -  Presence of clinical criteria consistent with VABP

          -  High probability of VABP caused by Pseudomonas aeriginosa

        Key Exclusion Criteria:

          -  Known or suspected community-acquired bacterial pneumonia or viral, fungal, or
             parasitic pneumonia

          -  Known hypersensitivity or contra-indications to beta-lactam antibiotics,
             aminoglycosides, quinolones, colistin, or subjects with a clinically significant
             history of anaphylactic reaction

          -  Severe liver or renal impairment

          -  Women who are pregnant or nursing, or who are of chilbearing potential and unwilling
             to use acceptable method of birth control
Clinical trial NCT03421379 (phase 3, status: completed)
Conditions: diabetes mellitus
ICD codes: P70.2, O24.92, Z83.3, E10.65, E10.9, E11.65, E11.9
Drugs: glucagon nasal powder, glucagon hydrochloride solution
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, N[C@@H](CCCNC(N)=N)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Participants with Type 1 diabetes (T1D) or Type 2 diabetes (T2D)

          -  Body mass Index (BMI) of 18.5 to 30.0 kilograms per meter squared (kg/m2) for T1D, or
             18.5 to 35.0 kg/m2 for T2D

          -  Hemoglobin A1c (HbA1c) ≤10%

        Exclusion Criteria:

          -  Have significant changes in insulin regimen and/ or unstable blood sugar control
             within the past 3 month

          -  Have received a total daily dose of insulin >1.2 units per kilogram (U/kg)
Clinical trial NCT03433677 (phase 3, status: completed)
Conditions: diabetes type 1
ICD codes: E10.65, E10.9, E10.21, E10.36, E10.41, E10.42, E10.44
Drugs: ly900014, insulin lispro
SMILES: [Na+].[Na+].[O-]P([O-])(F)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosed with type 1 diabetes and have been using insulin continuously for at least
             12 months.

          -  Using an insulin pump with 'rapid-acting insulin' for at least 6 months and using the
             same rapid-acting insulin for at least the past 30 days.

          -  Have experience using Continuous Glucose Monitoring (CGM) or Flash Glucose Monitoring
             (FGM) for at least 60 days during the past 12 months.

          -  Have hemoglobin A1c values ≤8.5%, as determined by the central laboratory at
             screening.

          -  Have a body mass index (BMI) of ≤35 kilograms per meter squared at screening.

          -  Have been using the MiniMed 530G or 630G (US) or the MiniMed 640G (EU) insulin pump
             for at least the past 30 days.

        Exclusion Criteria:

          -  Have had more than 1 emergency treatment for very low blood glucose in the last 6
             months.

          -  Have had more than 1 emergency treatment for poor glucose control (hyperglycemia or
             diabetic ketoacidosis) in the last 6 months.

          -  Have significant insulin resistance defined as having received a total daily dose of
             insulin >1.2 units per kilogram (U/kg) at screening, as determined by the average
             total daily insulin dose over the 3 days prior to screening divided by weight in
             kilograms based on investigator review of the participant's pump history.

          -  Have significant lipohypertrophy, lipoatrophy, or scars within the subcutaneous tissue
             in areas of infusion or have a history of abscess at an infusion site within the last
             90 days prior to screening.

          -  Are receiving any oral or injectable medication intended for the treatment of diabetes
             mellitus other than rapid-acting analog insulin via CSII in the 90 days prior to
             screening. Occasional pen or syringe injection of insulin is allowed, for example, due
             to pump malfunction or unexplained hyperglycemia not responsive to pump correction
             bolus.

          -  Taking certain diabetes medications that are not allowed for study participation.

          -  Have major problems with heart, kidneys, liver, or have a blood disorder.

          -  Have had or are now being treated for certain types of cancer that prevents study
             participation.
Clinical trial NCT03435302 (phase 3, status: unknown status)
Conditions: melanoma
ICD codes: C43.0, C43.31, D03.9, C43.51, C43.9, D03.0, C43.4
Drugs: temozolomide plus cisplatin, high-dose ifn-a2b
SMILES: CSCC[C@H](N)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          1. Age more than 18 years;

          2. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;

          3. Pathologically confirmed diagnosis of mucosal melanoma;

          4. Completely resected primary tumor (once regional lymph nodes were involved, diagnosed
             by clinical or imaging examinations, lymphadenectomy was conducted);

          5. No prior systemic adjuvant therapy or regional radiotherapy;

          6. No evidence of distant metastatic disease evaluated by means of lymph nodes
             ultrasound, endoscopy, and ultrasound of anorectum and genitourinary tract,
             single-photon emission computed tomography (CT) of bone, and whole-body spiral CT or
             positron emission tomography-CT (PET-CT);

          7. Normal bone marrow function; and adequate liver and renal function [including white
             blood cell (WBC) count > 3,000/mm^3;absolute neutrophil count > 1,500/mm^3; platelets
             >100,000/mm^3; serum creatinine less than two times of the upper limit of normal
             (ULN); bilirubin less than 1.5 times of ULN; aspartate aminotransferase (AST) and
             alanine aminotransferase (ALT) less than 2.5 times of ULN; international normalized
             ratio less than 1.5 times of ULN; and partial thromboplastin time less than ULN].

        Exclusion Criteria:

          1. Cutaneous melanoma or ocular melanoma or melanoma of unknown primary site;

          2. Incomplete resection or primary tumor unable to be resected;

          3. A second cancer diagnosis;

          4. Definite medical history of cirrhoses of the liver or autoimmune diseases;

          5. Severe depression; and pregnant or lactating female.
Clinical trial NCT03447249 (phase 3, status: completed)
Conditions: cystic fibrosis
ICD codes: E84.9, Z14.1, E84.0, E84.11, E84.8, E84.19, P09.4
Drugs: vx-659/tez/iva, iva, placebo
SMILES: CC(C)(C)C1=CC(=C(O)C=C1NC(=O)C1=CNC2=CC=CC=C2C1=O)C(C)(C)C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Key Inclusion Criteria:

          -  Heterozygous for F508del and an MF mutation (as defined in the protocol)

          -  Forced expiratory volume in 1 second (FEV1) value ≥40% and ≤90% of predicted mean for
             age, sex, and height

        Key Exclusion Criteria:

          -  Clinically significant cirrhosis with or without portal hypertension

          -  Lung infection with organisms associated with a more rapid decline in pulmonary status

          -  Solid organ or hematological transplantation

        Other protocol defined Inclusion/Exclusion criteria may apply
Clinical trial NCT03460990 (phase 3, status: completed)
Conditions: cystic fibrosis
ICD codes: E84.9, Z14.1, E84.0, E84.11, E84.8, E84.19, P09.4
Drugs: vx-659/tez/iva, tez/iva, iva, placebo, placebo
SMILES: CC(C)(CO)C1=CC2=CC(NC(=O)C3(CC3)C3=CC=C4OC(F)(F)OC4=C3)=C(F)C=C2N1C[C@@H](O)CO, CC(C)(C)C1=CC(=C(O)C=C1NC(=O)C1=CNC2=CC=CC=C2C1=O)C(C)(C)C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Key Inclusion Criteria:

          -  Homozygous for the F508del mutation (F/F)

          -  Forced expiratory volume in 1 second (FEV1) value ≥40% and ≤90% of predicted mean for
             age, sex, and height

        Key Exclusion Criteria:

          -  Clinically significant cirrhosis with or without portal hypertension

          -  Lung infection with organisms associated with a more rapid decline in pulmonary status

          -  Solid organ or hematological transplantation

        Other protocol defined Inclusion/Exclusion criteria may apply
Clinical trial NCT03463031 (phase 3, status: completed)
Conditions: seasonal allergic rhinitis (sar)
ICD codes: J30.2
Drugs: gsp 301 ns, gsp 301 placebo ns
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          1. Male and female subjects aged ≥6 to <12 years

          2. Clinical history of SAR (at least 2 years) with exacerbations during the study season
             for the relevant seasonal allergen (e.g., tree/grass pollen)

          3. Demonstrated sensitivity to at least 1 seasonal allergen through positive skin prick
             test within 12 months prior to screening

          4. A 12-hour rTNSS value ≥6 out of a possible 12 for the morning assessment at screening

          5. Signed informed consent/assent form (subject and parent/caregiver/legal guardian)

        Exclusion Criteria:

          1. Females of childbearing potential or pregnant

          2. Plans to travel outside the known pollen area for the investigational site for 24
             hours or longer during the last 7 days of the run-in period.

          3. History of anaphylaxis and/or other severe local reaction(s) to skin testing

          4. History and evidence of acute or significant chronic sinusitis or chronic purulent
             post nasal drip

          5. Subjects with an active pulmonary disorder or infection.

          6. Subjects with posterior subcapsular cataracts or glaucoma